Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Favored Organic product for Seniors' Prosperity: Make Your Determination - 2Twelve injured near Beit Shemesh, reports of shrapnel impact in Eilat as Iran targets Israel
- 32026 Golden Globes live updates: Red carpet arrivals will kick off the night; Nikki Glaser set to host
- 4Nurturing Hacks: Astuteness from Experienced Mothers and Fathers
- 5Allow Innovative Progressions To have a Massive Effect
- David Duchovny's new thriller has him stripping down at 65. But its chilling premise hits close to home.
- Record-breaking 'space laser' erupts from merging galaxies 8 billion light-years away
- The 1 question we have to ask ourselves about the Taylor Frankie Paul 'Bachelorette' scandal
- Christopher Nolan's 'The Odyssey' trailer: See Anne Hathaway, Matt Damon and Tom Holland in 1st look at movie
- ONE returns to Red Sea with new service
- Fundamental Monetary Guidance for Going into Business
- Agios Pharma shares jump as US FDA expands approval for its blood disorder drug
- How Mars 'punches above its weight' to influence Earth's climate
- Five held on suspicion of planning attack on German Christmas market
